AGM/EGMApr 30, 2026, 04:19 PM
IKT to Hold 2026 Annual Meeting; Proposes 3M Share Increase to Equity Plan
AI Summary
Inhibikase Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026. Key proposals include the election of two Class III directors, ratification of CohnReznick LLP as the independent auditor, and approval of an amendment to the certificate of incorporation to limit officer liability. Stockholders will also vote on increasing the authorized shares for the 2020 Equity Incentive Plan by 3,000,000 shares and advisory votes on executive compensation and its frequency.
Key Highlights
- Inhibikase Therapeutics to hold 2026 Annual Meeting of Stockholders virtually on June 26, 2026.
- Stockholders to elect two Class III directors, Arvind Kush and Dennis Berman, to serve until 2029.
- Proposal to ratify CohnReznick LLP as independent auditor for fiscal year ending December 31, 2026.
- Proposal to amend certificate of incorporation to limit officer liability as permitted by Delaware law.
- Proposal to increase authorized shares for 2020 Equity Incentive Plan by 3,000,000 shares.
- Advisory vote on named executive officer compensation and frequency of future advisory votes.
- Record date for voting is April 27, 2026, with 132,032,636 shares outstanding.
Price Impact
More from IKT